{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:33:02Z","timestamp":1773437582850,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"S17","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007378","name":"UFJF","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-020-03845-3","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T01:02:38Z","timestamp":1607907758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals"],"prefix":"10.1186","volume":"21","author":[{"name":"Collaborative Group for Studies of Yellow Fever Vaccine","sequence":"first","affiliation":[]},{"given":"Carla Rezende Barbosa","family":"Bonin","sequence":"first","affiliation":[]},{"given":"Guilherme C\u00f4rtes","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Reinaldo","family":"de Menezes Martins","sequence":"additional","affiliation":[]},{"given":"Luiz Antonio Bastos","family":"Camacho","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[]},{"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[]},{"given":"Sheila Maria Barbosa","family":"de Lima","sequence":"additional","affiliation":[]},{"given":"Ana Carolina","family":"Campi-Azevedo","sequence":"additional","affiliation":[]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[]},{"given":"Rodrigo Weber","family":"dos Santos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-9509","authenticated-orcid":false,"given":"Marcelo","family":"Lobosco","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"issue":"1","key":"3845_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12865-018-0252-1","volume":"19","author":"CR Bonin","year":"2018","unstructured":"Bonin CR, Fernandes GC, dos Santos RW, Lobosco M. A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine. BMC Immunol. 2018;19(1):15.","journal-title":"BMC Immunol"},{"key":"3845_CR2","doi-asserted-by":"crossref","unstructured":"Siegrist C-A. Vaccine immunology. In: Plotkin\u2019s vaccines. Amsterdam: Elsevier; 2018. p. 16\u201334.","DOI":"10.1016\/B978-0-323-35761-6.00002-X"},{"issue":"4","key":"3845_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.4161\/hv.22982","volume":"9","author":"RM Martins","year":"2013","unstructured":"Martins RM, Maia MdLS, Farias RHG, Camacho LAB, Freire MS, Galler R, Yamamura AMY, Almeida LFC, Lima SMB, Nogueira RMR, et al. 17dd yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccines Immunother. 2013;9(4):879\u201388.","journal-title":"Hum Vaccines Immunother"},{"issue":"17","key":"3845_CR4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.drudis.2006.07.010","volume":"11","author":"N Kumar","year":"2006","unstructured":"Kumar N, Hendriks BS, Janes KA, de Graaf D, Lauffenburger DA. Applying computational modeling to drug discovery and development. Drug Discov Today. 2006;11(17):806\u201311. https:\/\/doi.org\/10.1016\/j.drudis.2006.07.010.","journal-title":"Drug Discov Today"},{"issue":"31","key":"3845_CR5","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1016\/S0264-410X(01)00145-1","volume":"19","author":"ASD Groot","year":"2001","unstructured":"Groot ASD, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine. 2001;19(31):4385\u201395. https:\/\/doi.org\/10.1016\/S0264-410X(01)00145-1.","journal-title":"Vaccine"},{"key":"3845_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.03.006","author":"S Parvizpour","year":"2020","unstructured":"Parvizpour S, Pourseif MM, Razmara J, Rafi MA, Omidi Y. Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discov Today. 2020;. https:\/\/doi.org\/10.1016\/j.drudis.2020.03.006.","journal-title":"Drug Discov Today"},{"key":"3845_CR7","doi-asserted-by":"publisher","first-page":"110172","DOI":"10.1016\/j.jtbi.2020.110172","volume":"490","author":"P Tanwer","year":"2020","unstructured":"Tanwer P, Kolora SRR, Babbar A, Saluja D, Chaudhry U. Identification of potential therapeutic targets in neisseria gonorrhoeae by an in-silico approach. J Theor Biol. 2020;490:110172. https:\/\/doi.org\/10.1016\/j.jtbi.2020.110172.","journal-title":"J Theor Biol"},{"key":"3845_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-019-3045-5","volume":"20","author":"M Pennisi","year":"2019","unstructured":"Pennisi M, Russo G, Sgroi G, Bonaccorso A, Parasiliti PG, Fichera E, Mitra D, Walker K, Cardona P-J, Amat M, Viceconti M, Pappalardo F. Predicting the artificial immunity induced by ruti\u00ae vaccine against tuberculosis using universal immune system simulator (UISS). BMC Bioinform. 2019;20:1\u201310. https:\/\/doi.org\/10.1186\/s12859-019-3045-5.","journal-title":"BMC Bioinform"},{"issue":"7","key":"3845_CR9","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.sjbs.2018.08.019","volume":"26","author":"EH Ibrahim","year":"2019","unstructured":"Ibrahim EH, Taha R, Ghramh HA, Kilany M. Development of Rift Valley fever (RVF) vaccine by genetic joining of the RVF-glycoprotein Gn with the strong adjuvant subunit B of cholera toxin (CTB) and expression in bacterial system. Saudi J Biol Sci. 2019;26(7):1676\u201381. https:\/\/doi.org\/10.1016\/j.sjbs.2018.08.019.","journal-title":"Saudi J Biol Sci"},{"key":"3845_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.04.191","author":"M Pritam","year":"2020","unstructured":"Pritam M, Singh G, Swaroop S, Singh AK, Pandey B, Singh SP. A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria. Int J Biol Macromol. 2020;. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.04.191.","journal-title":"Int J Biol Macromol"},{"key":"3845_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fimmu.2020.00442","volume":"11","author":"AS De Groot","year":"2020","unstructured":"De Groot AS, Moise L, Terry F, Gutierrez AH, Hindocha P, Richard G, Hoft DF, Ross TM, Noe AR, Takahashi Y, Kotraiah V, Silk SE, Nielsen CM, Minassian AM, Ashfield R, Ardito M, Draper SJ, Martin WD. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol. 2020;11:442. https:\/\/doi.org\/10.3389\/fimmu.2020.00442.","journal-title":"Front Immunol"},{"key":"3845_CR12","doi-asserted-by":"publisher","first-page":"104320","DOI":"10.1016\/j.meegid.2020.104320","volume":"82","author":"M Bhattacharya","year":"2020","unstructured":"Bhattacharya M, Sharma AR, Sharma G, Patra P, Mondal N, Patra BC, Lee S-S, Chakraborty C. Computer aided novel antigenic epitopes selection from the outer membrane protein sequences of aeromonas hydrophila and its analyses. Infect Genet Evol. 2020;82:104320. https:\/\/doi.org\/10.1016\/j.meegid.2020.104320.","journal-title":"Infect Genet Evol"},{"issue":"1","key":"3845_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13071-020-04064-8","volume":"13","author":"MAA Khan","year":"2020","unstructured":"Khan MAA, Ami JQ, Faisal K, Chowdhury R, Ghosh P, Hossain F, Abd El\u00a0Wahed A, Mondal D. An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes. Parasit Vectors. 2020;13(1):196.","journal-title":"Parasit Vectors"},{"key":"3845_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.phrs.2014.08.006","volume":"92","author":"F Pappalardo","year":"2015","unstructured":"Pappalardo F, Flower D, Russo G, Pennisi M, Motta S. Computational modelling approaches to vaccinology. Pharmacol Res. 2015;92:40\u20135.","journal-title":"Pharmacol Res"},{"issue":"2","key":"3845_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/21645515.2017.1264774","volume":"13","author":"CRB Bonin","year":"2017","unstructured":"Bonin CRB, Fernandes GC, dos Santos RW, Lobosco M. Mathematical modeling based on ordinary differential equations: a promising approach to vaccinology. Hum Vaccines Immunother. 2017;13(2):484\u20139.","journal-title":"Hum Vaccines Immunother"},{"key":"3845_CR16","doi-asserted-by":"publisher","unstructured":"Bonin CB, Fernandes GC, dos Santos RW, Lobosco M. A simplified mathematical-computational model of the immune response to the yellow fever vaccine. In: 2017 IEEE international conference on bioinformatics and biomedicine (BIBM). Los Alamitos: IEEE Computer Society; 2017. p. 1425\u201332. https:\/\/doi.org\/10.1109\/BIBM.2017.8217872.","DOI":"10.1109\/BIBM.2017.8217872"},{"key":"3845_CR17","doi-asserted-by":"crossref","unstructured":"Bonin CRB, Fernandes GC, Menezes RM, Camacho LAB, da Mota LMH, de Lima SMB, Campi-Azevedo AC, Martins-Filho OA, dos Santos RW, Lobosco M. Quantitative validation of a yellow fever vaccine model. In: 2019 IEEE international conference on bioinformatics and biomedicine (BIBM); 2019. p. 2113\u201320.","DOI":"10.1109\/BIBM47256.2019.8983128"},{"key":"3845_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2014.00177","author":"D Le","year":"2015","unstructured":"Le D, Miller JD, Ganusov VV. Mathematical modeling provides kinetic details of the human immune response to vaccination. Front Cell Infect Microbiol. 2015;. https:\/\/doi.org\/10.3389\/fcimb.2014.00177.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"3845_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jir439","volume":"204","author":"M Luiza-Silva","year":"2011","unstructured":"Luiza-Silva M, Campi-Azevedo AC, Batista MA, Martins MA, Avelar RS, da Silveira\u00a0Lemos D, Bastos\u00a0Camacho LA, de Menezes\u00a0Martins R, de\u00a0Lourdes\u00a0de Sousa\u00a0Maia M, Guedes\u00a0Farias RH, et al. Cytokine signatures of innate and adaptive immunity in 17dd yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis. 2011;204(6):873\u201383.","journal-title":"J Infect Dis"},{"issue":"12","key":"3845_CR20","doi-asserted-by":"publisher","first-page":"49828","DOI":"10.1371\/journal.pone.0049828","volume":"7","author":"AC Campi-Azevedo","year":"2012","unstructured":"Campi-Azevedo AC, de Ara\u00fajo-Porto LP, Luiza-Silva M, Batista MA, Martins MA, Sathler-Avelar R, da Silveira-Lemos D, Camacho LAB, de Menezes\u00a0Martins R, de Sousa\u00a0Maia MdL, et al. 17dd and 17d-213\/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PloS One. 2012;7(12):49828.","journal-title":"PloS One"},{"issue":"2","key":"3845_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","volume":"12","author":"AC Campi-Azevedo","year":"2016","unstructured":"Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, Santos RA, Batista MA, Campos FM, Pacheco-Porto L, et al. Booster dose after 10 years is recommended following 17dd-yf primary vaccination. Hum Vaccines Immunother. 2016;12(2):491\u2013502.","journal-title":"Hum Vaccines Immunother"},{"issue":"28","key":"3845_CR22","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1016\/j.vaccine.2018.05.041","volume":"36","author":"RdM Martins","year":"2018","unstructured":"Martins RdM, Maia MdLS, Lima SMBd, Noronha TGd, Xavier JR, Camacho LAB, Albuquerque EMd, Farias RHG, Castro TdMd, Homma A, et al. Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine. 2018;36(28):4112\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"3845_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1471-2334-14-391","volume":"14","author":"AC Campi-Azevedo","year":"2014","unstructured":"Campi-Azevedo AC, de Almeida\u00a0Estevam P, Coelho-dos-Reis JG, Peruhype-Magalh\u00e3es V, Villela-Rezende G, Quaresma PF, Maia MdLS, Farias RHG, Camacho, L.A.B., da Silva\u00a0Freire M, et al. Subdoses of 17dd yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect Dis. 2014;14(1):391.","journal-title":"BMC Infect Dis"},{"key":"3845_CR24","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1016\/j.vaccine.2019.05.048","volume":"37","author":"LAB Camacho","year":"2019","unstructured":"Camacho LAB, Collaborative group for studies on yellow fever vaccines, et al. Duration of immunity in recipients of two doses of 17dd yellow fever vaccine. Vaccine. 2019;37:5129\u201335.","journal-title":"Vaccine"},{"issue":"1","key":"3845_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13075-019-1854-6","volume":"21","author":"CdC Ferreira","year":"2019","unstructured":"Ferreira CdC, Campi-Azevedo AC, Peruhype-Magalh\u0101es V, Coelho-dos-Reis JG, Antonelli LRdV, Torres K, Freire LC, Costa-Rocha IAd, Oliveira ACV, Maia MdLdS, et al. Impact of synthetic and biological immunomodulatory therapy on the duration of 17dd yellow fever vaccine-induced immunity in rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):75.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3845_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","volume":"40","author":"M Sim\u00f5es","year":"2012","unstructured":"Sim\u00f5es M, Camacho LAB, Yamamura AM, Miranda EH, Cajaraville ACR, da Silva\u00a0Freire M. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-prnt) in detection of yellow fever virus antibodies. Biologicals. 2012;40(6):399\u2013404.","journal-title":"Biologicals"},{"key":"3845_CR27","first-page":"1720","volume-title":"Plotkin\u2019s Vac","author":"SPWOPOKM Edwards","year":"2018","unstructured":"Edwards SPWOPOKM. Plotkin\u2019s Vac. 7th ed. New York: Elsevier; 2018. p. 1720.","edition":"7"},{"key":"3845_CR28","volume-title":"Fundamental immunology","author":"WE Paul","year":"2012","unstructured":"Paul WE. Fundamental immunology. 7th ed. Philadelphia: Wolters Kluwer Health; 2012.","edition":"7"},{"issue":"6","key":"3845_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1472-8206.2008.00633.x","volume":"22","author":"S Goutelle","year":"2008","unstructured":"Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008;22(6):633\u201348.","journal-title":"Fundam Clin Pharmacol"},{"key":"3845_CR30","unstructured":"Odeint. Odeint\u2019s homepage; 2020. Accessed on Oct 2020. http:\/\/docs.scipy.org"},{"key":"3845_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","volume":"38","author":"LAB Camacho","year":"2004","unstructured":"Camacho LAB, Freire MdS, Leal MdLF, Aguiar SGd, Nascimento JPd, Iguchi T, Lozana JdA, Farias RHG. Immunogenicity of who-17d and brazilian 17dd yellow fever vaccines: a randomized trial. Rev. saude publica. 2004;38:671\u20138.","journal-title":"Rev. saude publica"},{"issue":"7","key":"3845_CR32","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.4161\/21645515.2014.990854","volume":"11","author":"AG Fernandes-Monteiro","year":"2015","unstructured":"Fernandes-Monteiro AG, Trindade GF, Yamamura AM, Moreira OC, de Paula VS, Duarte ACM, Britto C, Lima SMB. New approaches for the standardization and validation of a real-time qpcr assay using taqman probes for quantification of yellow fever virus on clinical samples with high quality parameters. Hum Vaccines Immunother. 2015;11(7):1865\u201371.","journal-title":"Hum Vaccines Immunother"},{"issue":"11","key":"3845_CR33","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41590-018-0210-3","volume":"19","author":"JL Slon Campos","year":"2018","unstructured":"Slon Campos JL, Mongkolsapaya J, Screaton GR. The immune response against flaviviruses. Nat Immunol. 2018;19(11):1189\u201398. https:\/\/doi.org\/10.1038\/s41590-018-0210-3.","journal-title":"Nat Immunol"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03845-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-020-03845-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03845-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T01:05:38Z","timestamp":1607907938000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-020-03845-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"journal-issue":{"issue":"S17","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3845"],"URL":"https:\/\/doi.org\/10.1186\/s12859-020-03845-3","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The collection of data for this study was undertaken under a larger project that was approved by the local ethics commitee (CEP IPEC\/FIOCRUZ \u2116 052\/2008, CEP INI\/FIOCRUZ \u2116 1.976.767, and CEP ENSP\/FIOCRUZ  508.650) All patients filled an institutional form consenting to participate of the studies were data were taken from.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patient data were anonymised before evaluation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Researchers and collaborators include employees of several units of Oswaldo Cruz Foundation (FIOCRUZ, linked to Brazilian Ministry of Health), including Bio-Manguinhos, which is responsible for the production of the YFV used in Brazil.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"551"}}